

Translation

Supply Plan of "Tamiflu[®]" Anti-influenza Drug

October 14, 2010 (Tokyo) - Chugai Pharmaceutical Co., Ltd. ("Chugai") [Head Office: Chuo-ku, Tokyo. President: Osamu Nagayama] announced today the supply plan up until March 2011, of the anti-influenza drug "Tamiflu[®] Capsule 75" and "Tamiflu[®] Dry Syrup 3%" (generic name: oseltamivir phosphate) imported from F. Hoffmann-La Roche Ltd. [Head Office: Basel, Switzerland. CEO: Severin Schwan] for production and marketing in Japan.

Following the widespread of the A/H1N1 influenza strain in the year 2009, a continued precaution is necessary for the second season, the coming 2010/2011 influenza season. Chugai is determined to be ready for the supply of Tamiflu accompanied by a speedy provision of information including data on safety, so that the medical professionals will be able to prescribe Tamiflu with confidence.

Chugai has already prepared 12.4 million treatment courses of Tamiflu and is ready to supply more according to the size of the epidemic.

Chugai is committed to be fully prepared as a responsible supplier of the anti-influenza treatment.

Chugai stock available for supply (as of end of September 2010)

Tamiflu [®] Capsule 75	8.8 million treatment courses
Tamiflu [®] Dry Syrup 3%	3.6 million treatment courses
Total of 12.4 million treatment courses	

*Supply amount of last season (August 2009 – March 2010):
approximately 9.76 million treatment courses

Tamiflu[®] is trademark of F.Hoffmann-La Roche Ltd., Basel, Switzerland.